A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
London, Det Forenede Kongerige, E1 2AX
- hVIVO Services Ltd
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subject is in good health as determined by the Investigator based on medical history, physical examination, and routine laboratory tests at a screening evaluation.
- Male or female, aged between 18 and 55 years inclusive
- Body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 30kg/m2
- Subject must provide written informed consent
- Serosuitable to the challenge virus.
Exclusion Criteria:
- History or evidence of any clinically significant or currently active major clinical illness.
- Any significant abnormality altering the anatomy of the nose or nasopharynx
- Any nasal or sinus surgery within six months of the study
- Abnormal lung function
- Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.
- Presence of cold like symptoms and/or fever on admission for the study
- History or currently active symptoms suggestive of upper or lower respiratory tract infection within 6 weeks of the study
- History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: PC786
Repeat dose
|
Repeat doses
|
|
Placebo komparator: Placebo/vehicle
Repeat dose
|
Repeat doses
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
RSV viral load
Tidsramme: Baseline to Day 28
|
AUC 0-t for RSV viral load measured in nasal washes by reverse transcription quantitative polymerase chain reaction (RT-qPCR)
|
Baseline to Day 28
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants reporting one or more treatment-emergent adverse event (TEAE)
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who discontinue due to an adverse event
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at least once post dose
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for vital signs assessments at least once post dose
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for safety laboratory assessments at least once post dose
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Number of participants who meet the markedly abnormal criteria for spirometry (FEV1 & FVC measured together) assessments at least once post dose
Tidsramme: Screening to Day 28
|
Screening to Day 28
|
|
|
Area under the plasma concentration versus time curve (AUC) of PC786 measured in plasma
Tidsramme: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Maximum observed concentration (Cmax) of PC786 measured in plasma
Tidsramme: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Time maximum concentration observed (Tmax) of PC786 measured in plasma
Tidsramme: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Apparent terminal half life (T1/2) of PC786 measured in plasma
Tidsramme: Pre-dose and at multiple time points to Day 12
|
Pre-dose and at multiple time points to Day 12
|
|
|
Determination of nasal concentrations of PC786
Tidsramme: Pre-dose and at multiple time points to Day 28
|
PC786 concentrations in mucosal lining fluid collected using synthetic absorptive matrix
|
Pre-dose and at multiple time points to Day 28
|
|
Comparison of mucus production following treatment with PC786 or placebo post viral inoculation
Tidsramme: Baseline to Day 12
|
Reduction in weight of mucus produced post viral infection
|
Baseline to Day 12
|
|
Comparison of the effect of treatment with PC786 or placebo on RSV symptoms
Tidsramme: Baseline to Day 12
|
Composite score of self-reported symptoms on a symptom diary card.
Nasal symptoms, sneezing, sore throat, cough, headache, wheezing, chest tightness, shortness of breath, joint aches, feverishness, malaise, earache are assessed using a score of 0 (no symptoms), 1 (just noticeable), 2 (bothersome but able to participate in activities), 3 (bothersome and not able to participate in activities)
|
Baseline to Day 12
|
|
Change in viral load measured in nasal wash
Tidsramme: Baseline to Day 12
|
Change in viral load before first dose of PC786 to Day 12
|
Baseline to Day 12
|
|
Time to non-detectability of virus measured in nasal wash
Tidsramme: Baseline to Day 12
|
Baseline to Day 12
|
|
|
Peak viral load measured in nasal wash
Tidsramme: Baseline to Day 12
|
Baseline to Day 12
|
|
|
Time peak viral load observed measured in nasal wash
Tidsramme: Baseline to Day 12
|
Baseline to Day 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Bryan J Murray, MBBS, hVIVO Services Ltd
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PC_RSV_003
- 2017-002563-18 (EudraCT nummer)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .